Dashboard
Manage Tickers

ATRA Atara Biotherapeutics, Inc.

Nasdaq atarabio.com


$ 11.64 $ 1.07 (10.12 %)    

Thursday, 06-Nov-2025 10:10:22 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 616.50 $ -5.27 (-0.85 %)
DIA $ 470.43 $ -1.61 (-0.34 %)
SPY $ 673.48 $ -2.99 (-0.44 %)
TLT $ 89.69 $ 0.13 (0.15 %)
GLD $ 366.31 $ -1.00 (-0.27 %)
$ 10.75
$ 10.57
$ 11.30 x 100
$ 11.62 x 100
$ 10.57 - $ 11.64
$ 5.01 - $ 18.71
158,739
na
75.5M
$ 1.53
$ 13.03
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-07-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-08-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-09-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-04-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pierre-fabre-pharmaceuticals-takes-over-tabelecleucel-bla-from-atara-biotherapeutics-ahead-of-fda-priority-review-on-january-10-2026-for-first-us-ebv-ptld-therapy
Pierre Fabre Pharmaceuticals Takes Over Ta...
11/03/2025 14:18:45

Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved the...

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/17/2025 21:07:13

4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals
4 Biotechnology Stocks That Outshine In Mo...
09/29/2025 11:11:04

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

atara-biotherapeutics-greg-ciongoli-to-assume-the-role-of-chair-of-the-board-of-directors
Atara Biotherapeutics' Greg Ciongoli To As...
09/03/2025 22:03:16

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus...

atara-biotherapeutics-says-co-has-resumed-its-evaluation-of-strategic-options
Atara Biotherapeutics Says Co Has Resumed ...
08/11/2025 20:30:32

atara-biotherapeutics-q2-eps-019-beats-081-estimate-sales-1757m-beat-567m-estimate
Atara Biotherapeutics Q2 EPS $0.19 Beats $...
08/11/2025 20:13:10

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of...

atara-biotherapeutics-says-fda-accepts-filing-of-bla-for-tabelecleucel-indicated-as-monotherapy-for-treatment-of-patients-with-ebv-ptld-who-have-received-at-least-one-prior-therapy
Atara Biotherapeutics Says FDA Accepts Fil...
07/24/2025 12:20:13

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026If Approved, Tab-cel Would Be First Approved Thera...

pierre-fabre-pharma-announces-transfer-of-ind-application-for-tabelecleucel-from-its-partner-atara-biotherapeutics
Pierre Fabre Pharma Announces Transfer Of ...
07/15/2025 12:19:01

Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical programEnr...

atara-biotherapeutics-resubmits-tabelecleucel-biologics-license-application
Atara Biotherapeutics Resubmits Tabelecleu...
07/14/2025 12:01:03

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/18/2025 21:05:53

atara-biotherapeutics-q1-eps-350-beats-198-estimate-sales-9815m-beat-567m-estimate
Atara Biotherapeutics Q1 EPS $3.50 Beats $...
05/15/2025 13:17:07

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of...

atara-biotherapeutics-prices-offering-of-834237-shares-at-661shr-and-pre-funded-warrants-at-66099-per-pre-funded-warrant-share-in-underwritten-registered-direct-offering
Atara Biotherapeutics Prices Offering Of 8...
05/15/2025 12:36:02

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/06/2025 12:08:25

atara-biotherapeutics-provides-regulatory-updates-on-ebvallo-fda-lifts-clinical-hold-enabling-resumption-of-clinical-trials-fda-has-granted-a-type-a-meeting-to-discuss-path-forward-for-bla
Atara Biotherapeutics Provides Regulatory ...
05/05/2025 21:20:46

FDA lifts clinical hold enabling resumption of clinical trialsFDA has granted a Type A Meeting to discuss path forward for BLAA...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
04/24/2025 12:06:59

atara-biotherapeutics-transfers-full-manufacturing-responsibility-for-tabelecleucel-to-pierre-fabre-now-entitled-to-receive-up-to-550m-in-additional-potential-milestone-payments-upon-achieving-certain-regulatory-and-commercial-milestones-relating-to-tab-cel-including-up-to-40m-in-potential-regulatory-milestones-in-connection-with-the-approval-by-the-fda-of-a-bla-for-tab-cel
Atara Biotherapeutics Transfers Full Manuf...
04/04/2025 20:36:39

On March 31, 2025, Atara Biotherapeutics, Inc., (the "Company") entered into an Amendment (the "Amendment") to ...

canaccord-genuity-maintains-buy-on-atara-biotherapeutics-maintains-17-price-target
Canaccord Genuity Maintains Buy on Atara B...
03/11/2025 13:08:34

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $17 price target.

atara-biotherapeutics-q4-2024-gaap-eps-119-beats-358-estimate-sales-32753-miss-19148m-estimate
Atara Biotherapeutics Q4 2024 GAAP EPS $(1...
03/07/2025 21:03:45

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of...

hc-wainwright--co-reiterates-neutral-on-atara-biotherapeuticsto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
01/28/2025 12:09:30

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

hc-wainwright--co-reiterates-neutral-on-atara-biotherapeuticsto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
01/22/2025 12:51:22

HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) from Neutral to Neutral.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION